Forigerimod
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .
For research use only. We do not sell to patients.
- CAS No.: 497156-60-2
- Formula: C117H181N34O32PS
- Molecular Weight:2638.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MRL/lpr mice[4]
-
Dosage:100 μg in 100 μL saline per mouse
-
Administration:Intravenous administration, single
-
Result:Corrected the cell content and distribution in MRL/lpr salivary glands.
Corrected the defective of autophagy processes in SGs of MRL/lpr mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 497156-60-2
-
Molecular Weight 2638.94
-
Formula C117H181N34O32PS
-
Synonyms
IPP-201101
-
Sequence
Arg-Ile-His-Met-Val-Tyr-Ser-Lys-Arg-{pSer}-Gly-Lys-Pro-Arg-Gly-Tyr-Ala-Phe-Ile-Glu-Tyr
-
Sequence Shortening
RIHMVYSKR-{pSer}-GKPRGYAFIEY
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. [Content Brief]
[2]. Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701. [Content Brief]
[3]. Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830-5. [Content Brief]
[4]. Baihui Li, et al. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. J Autoimmun. 2018 Jun;90:132-145. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz